“Vertex is the first drugmaker in decades to gain U.S. approval for a new type of pain medicine.”

Last weekend we saw another market correction.

This time markets dropped after President Donald Trump announced he would start imposing tariffs on Canada and Mexico starting this Tuesday.

Futures for Wall Street’s S&P 500 and tech-heavy Nasdaq fell 1.6%. Futures on the Russell 2000 index of small cap stocks – viewed as major beneficiaries of Trump’s policies – fell 2.23%.

For more information on how we play down markets, click here to learn about The Dark Ticker.

The truth is these market corrections provide major dip buying opportunities, and when it comes to my trading plan this week, I have one stock I want you to know about.

Vertex Pharmaceuticals (VRTX) is on my watchlist for one big reason.

You see… non-addictive pain management has been a major unmet market need for many, many years.

And as of Friday – VRTX now might be the only solution in town.

Last week, The Food and Drug Administration approved Vertex Pharmaceuticals’ non-opioid painkiller pill, a new alternative for pain relief that comes without the risk of addiction.

With the approval, VRTX is now the first drugmaker in decades to gain U.S. approval for a new type of pain medicine.

The drug, known as Journavx, is specifically approved for the treatment of moderate to severe acute pain, which is usually caused by injury, surgery, illness, trauma or painful medical procedures and is likely to ease with time.

And the sad truth is…

Almost 10% of patients with acute pain who are treated initially with an opioid will go on to have prolonged opioid use. Plus, roughly 85,000 people will develop opioid use disorder annually, Vertex said in a statement.

That’s why I believe this latest FDA approval for VRTX is a big deal.

I’ve already traded VRTX in The War Room for a 50% gain in less than 1 trading day on Friday.

But I think this news is so big that I’m watching the stock all week for re-entry on another pop.

Popular posts